Ionis Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Amgen and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Ionis Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Amgen and Ionis Pharmaceuticals, as reported by MarketBeat.

Amgen presently has a consensus target price of $254.08, suggesting a potential upside of 13.02%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Amgen.

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Amgen has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Profitability

This table compares Amgen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Amgen beats Ionis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Gilead Sciences and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Ionis Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and Ionis Pharmaceuticals, as reported by MarketBeat.

Gilead Sciences presently has a consensus target price of $76.1538, suggesting a potential upside of 26.86%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Gilead Sciences.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Ionis Pharmaceuticals beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Vertex Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.

Vertex Pharmaceuticals presently has a consensus target price of $290.5862, suggesting a potential upside of 28.18%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Regeneron Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Regeneron Pharmaceuticals currently has a consensus target price of $628.52, indicating a potential upside of 22.27%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Ionis Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

78.9% of Biogen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Biogen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Biogen and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Biogen and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Biogen currently has a consensus target price of $305.9032, indicating a potential upside of 25.48%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Seagen (NASDAQ:SGEN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Seagen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Seagen and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Seagen and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Seagen currently has a consensus target price of $176.75, indicating a potential upside of 4.51%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Seagen.

Summary

Ionis Pharmaceuticals beats Seagen on 9 of the 15 factors compared between the two stocks.